Hepatitis C Treatment in Underserved Populations

Status Enrolling by invitation

Clinical Trial Summary

The purpose of this study is to examine the feasibility, safety, and effectiveness of treating persons who are actively using illicit drugs for hepatitis C using a collaborative, multidisciplinary, integrated care model. We hypothesize that by maximizing facilitators and minimizing barriers to treatment we can enable drug users to receive effective treatment for hepatitis C.

Clinical Trial Description

This study examines the feasibility of integrated treatment for hepatitis C in active IDUs using a client-centered, multidisciplinary model that combines expert care in five domains: (a) antiviral pharmacotherapy for HCV infection; (b) substance abuse treatment; (c) psychiatric evaluation and treatment; (d) primary medical care; and (e) intensive, client-centered, case management. The Weill Cornell Medical College Center for the Study of Hepatitis C collaborates with community-based organizations providing services to injection drug users to provide multidisciplinary, integrated care using a model that combines the resources of culturally appropriate community-based agencies with those of a state-of-the-art tertiary care center. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01717560
Study type	Interventional
Source	Weill Medical College of Cornell University
Contact
Status	Enrolling by invitation
Phase	N/A
Start date	February 2005
Completion date	December 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01937975` - The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)	Phase 1
Completed	`NCT03673696` - The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects	Phase 1
Completed	`NCT02250001` - Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C	N/A
Completed	`NCT03088917` - 'Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat'
Completed	`NCT02207088` - Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease	Phase 3
Not yet recruiting	`NCT02865369` - Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment	N/A
Recruiting	`NCT02638233` - Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy	Phase 4
Not yet recruiting	`NCT02511496` - Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia	N/A
Completed	`NCT02788682` - Association of Vitamin D Binding Protein Polymorphisms With Response to HCV Therapy	N/A
Not yet recruiting	`NCT01949168` - A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV	Phase 2
Completed	`NCT01439776` - Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients	Phase 4
Recruiting	`NCT01360892` - Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography	N/A
Recruiting	`NCT01360879` - Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease	N/A
Completed	`NCT00968357` - Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed	Phase 2
Terminated	`NCT00962936` - Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection	Phase 1/Phase 2
Recruiting	`NCT01178749` - Exploration of Chronic Hepatitis C Infection Receiving 24-week Interferon-α With Ribavirin Treatments	N/A
Recruiting	`NCT00575627` - Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels	Phase 4
Completed	`NCT00537407` - A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment	Phase 2
Recruiting	`NCT00370617` - Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance	Phase 4
Completed	`NCT01684787` - Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients	Phase 4